Aged 0 4 0 4 B-age
18 5 7 5 7 B-lower_bound
years 8 13 8 13 I-lower_bound
or 14 16 14 16 O
older 17 22 17 22 O

Chronic 0 7 23 30 B-chronic_disease
or 8 10 31 33 O
current 11 18 34 41 O
active 19 25 42 48 B-chronic_disease
infection 26 35 49 58 I-chronic_disease
requiring 36 45 59 68 O
systemic 46 54 69 77 B-treatment
antibiotic 55 65 78 88 I-treatment
, 65 66 88 89 O
antifungal 67 77 90 100 B-treatment
, 77 78 100 101 O
or 79 81 102 104 O
antiviral 82 91 105 114 B-treatment
treatment 92 101 115 124 I-treatment

Confirmed 0 9 125 134 O
diagnosis 10 19 135 144 O
of 20 22 145 147 O
select 23 29 148 154 O
advanced 30 38 155 163 B-cancer
malignancy 39 49 164 174 I-cancer

Elderly 0 7 175 182 O
subjects 8 16 183 191 O
( 17 18 192 193 O
≥ 18 19 193 194 O
65 20 22 195 197 B-lower_bound
years 23 28 198 203 I-lower_bound
) 28 29 203 204 O
with 30 34 205 209 O
newly 35 40 210 215 O
diagnosed 41 50 216 225 O
AML 51 54 226 229 B-cancer
must 55 59 230 234 O
be 60 62 235 237 O
treatment 63 72 238 247 B-treatment
naive 73 78 248 253 O
and 79 82 254 257 O
unfit 83 88 258 263 O
for 89 92 264 267 O
intensive 93 102 268 277 B-treatment
chemotherapy 103 115 278 290 I-treatment

Life 0 4 291 295 B-clinical_variable
expectancy 5 15 296 306 I-clinical_variable
> 16 17 307 308 O
12 18 20 309 311 B-lower_bound
weeks 21 26 312 317 I-lower_bound
or 27 29 318 320 O
≥ 30 31 321 322 O
24 32 34 323 325 B-lower_bound
weeks 35 40 326 331 I-lower_bound
for 41 44 332 335 O
Part 45 49 336 340 O
3 50 51 341 342 O
and 52 55 343 346 O
Part 56 60 347 351 O
4 61 62 352 353 O
MF 63 65 354 356 O
subjects 66 74 357 365 O

Myelofibrosis 0 13 366 379 B-cancer
subjects 14 22 380 388 O
must 23 27 389 393 O
have 28 32 394 398 O
been 33 37 399 403 O
treated 38 45 404 411 O
with 46 50 412 416 O
ruxolitinib 51 62 417 428 B-treatment
for 63 66 429 432 O
≥ 67 68 433 434 O
6 69 70 435 436 B-lower_bound
months 71 77 437 443 I-lower_bound
with 78 82 444 448 O
a 83 84 449 450 O
stable 85 91 451 457 O
dose 92 96 458 462 O
for 97 100 463 466 O
≥ 101 102 467 468 O
8 103 104 469 470 B-lower_bound
weeks 105 110 471 476 I-lower_bound
( 111 112 477 478 O
acceptable 112 122 478 488 O
doses 123 128 489 494 O
are 129 132 495 498 O
5 133 134 499 500 O
mg 135 137 501 503 O
twice 138 143 504 509 O
daily 144 149 510 515 O
[ 150 151 516 517 O
BID 151 154 517 520 O
] 154 155 520 521 O
to 156 158 522 524 O
25 159 161 525 527 O
mg 162 164 528 530 O
BID 165 168 531 534 O
) 168 169 534 535 O

Not 0 3 536 539 O
currently 4 13 540 549 O
a 14 15 550 551 O
candidate 16 25 552 561 O
for 26 29 562 565 O
curative 30 38 566 574 B-treatment
treatment 39 48 575 584 I-treatment

Prior 0 5 585 590 O
receipt 6 13 591 598 O
of 14 16 599 601 O
a 17 18 602 603 O
PIM 19 22 604 607 B-treatment
inhibitor 23 32 608 617 I-treatment

Radiotherapy 0 12 618 630 B-treatment
within 13 19 631 637 O
the 20 23 638 641 O
2 24 25 642 643 B-upper_bound
weeks 26 31 644 649 I-upper_bound
prior 32 37 650 655 I-upper_bound
to 38 40 656 658 O
initiation 41 51 659 669 O
of 52 54 670 672 O
treatment 55 64 673 682 B-treatment

Received 0 8 683 691 O
an 9 11 692 694 O
investigational 12 27 695 710 B-treatment
agent 28 33 711 716 I-treatment
within 34 40 717 723 O
5 41 42 724 725 B-upper_bound
half 43 47 726 730 I-upper_bound
- 47 48 730 731 I-upper_bound
lives 48 53 731 736 I-upper_bound
or 54 56 737 739 O
14 57 59 740 742 O
days 60 64 743 747 O
, 64 65 747 748 O
whichever 66 75 749 758 O
is 76 78 759 761 O
longer 79 85 762 768 O
, 85 86 768 769 O
prior 87 92 770 775 O
to 93 95 776 778 O
receiving 96 105 779 788 O
the 106 109 789 792 O
first 110 115 793 798 O
dose 116 120 799 803 O
of 121 123 804 806 O
study 124 129 807 812 B-treatment
drug 130 134 813 817 I-treatment

Received 0 8 818 826 O
non 9 12 827 830 B-treatment
- 12 13 830 831 I-treatment
biologic 13 21 831 839 I-treatment
anticancer 22 32 840 850 I-treatment
medication 33 43 851 861 I-treatment
within 44 50 862 868 O
5 51 52 869 870 B-upper_bound
half 53 57 871 875 I-upper_bound
- 57 58 875 876 I-upper_bound
lives 58 63 876 881 I-upper_bound
prior 64 69 882 887 I-upper_bound
to 70 72 888 890 O
receiving 73 82 891 900 O
the 83 86 901 904 O
first 87 92 905 910 O
dose 93 97 911 915 O
of 98 100 916 918 O
study 101 106 919 924 B-treatment
drug 107 111 925 929 I-treatment
( 112 113 930 931 O
within 113 119 931 937 O
6 120 121 938 939 B-upper_bound
weeks 122 127 940 945 I-upper_bound
for 128 131 946 949 O
mitomycin 132 141 950 959 B-treatment
- 141 142 959 960 I-treatment
C 142 143 960 961 I-treatment
or 144 146 962 964 O
nitrosoureas 147 159 965 977 B-treatment
) 159 160 977 978 O
, 160 161 978 979 O
within 162 168 980 986 O
28 169 171 987 989 B-upper_bound
days 172 176 990 994 I-upper_bound
for 177 180 995 998 O
any 181 184 999 1002 O
antibodies 185 195 1003 1013 B-treatment
or 196 198 1014 1016 O
biological 199 209 1017 1027 B-treatment
therapies 210 219 1028 1037 I-treatment

Screening 0 9 1038 1047 O
corrected 10 19 1048 1057 B-clinical_variable
QT 20 22 1058 1060 I-clinical_variable
interval 23 31 1061 1069 I-clinical_variable
( 32 33 1070 1071 I-clinical_variable
QTc 33 36 1071 1074 I-clinical_variable
) 36 37 1074 1075 I-clinical_variable
interval 38 46 1076 1084 I-clinical_variable
> 47 48 1085 1086 O
470 49 52 1087 1090 B-lower_bound
milliseconds 53 65 1091 1103 I-lower_bound

Subjects 0 8 1104 1112 O
with 9 13 1113 1117 O
relapsed 14 22 1118 1126 O
/ 22 23 1126 1127 O
refractory 23 33 1127 1137 O
AML 34 37 1138 1141 B-cancer
must 38 42 1142 1146 O
have 43 47 1147 1151 O
received 48 56 1152 1160 O
either 57 63 1161 1167 O
induction 64 73 1168 1177 B-treatment
chemotherapy 74 86 1178 1190 I-treatment
for 87 90 1191 1194 O
AML 91 94 1195 1198 O
or 95 97 1199 1201 O
hypomethylating 98 113 1202 1217 B-treatment
agents 114 120 1218 1224 I-treatment
for 121 124 1225 1228 O
hematologic 125 136 1229 1240 B-chronic_disease
disease 137 144 1241 1248 I-chronic_disease
before 145 151 1249 1255 O
AML 152 155 1256 1259 O

Unresponsive 0 12 1260 1272 O
to 13 15 1273 1275 O
currently 16 25 1276 1285 O
available 26 35 1286 1295 O
therapy 36 43 1296 1303 B-treatment
and 44 47 1304 1307 O
there 48 53 1308 1313 O
is 54 56 1314 1316 O
no 57 59 1317 1319 O
standard 60 68 1320 1328 O
- 68 69 1328 1329 O
of 69 71 1329 1331 O
- 71 72 1331 1332 O
care 72 76 1332 1336 O
therapy 77 84 1337 1344 O
available 85 94 1345 1354 O
in 95 97 1355 1357 O
the 98 101 1358 1361 O
judgment 102 110 1362 1370 O
of 111 113 1371 1373 O
the 114 117 1374 1377 O
investigator 118 130 1378 1390 O

Willingness 0 11 1391 1402 O
to 12 14 1403 1405 O
undergo 15 22 1406 1413 O
a 23 24 1414 1415 O
pretreatment 25 37 1416 1428 B-treatment
bone 38 42 1429 1433 I-treatment
marrow 43 49 1434 1440 I-treatment
biopsy 50 56 1441 1447 I-treatment
and/or 57 63 1448 1454 O
aspirate 64 72 1455 1463 B-treatment
, 72 73 1463 1464 O
or 74 76 1465 1467 O
archival 77 85 1468 1476 O
sample 86 92 1477 1483 O
obtained 93 101 1484 1492 O
since 102 107 1493 1498 O
completion 108 118 1499 1509 O
of 119 121 1510 1512 O
most 122 126 1513 1517 O
recent 127 133 1518 1524 O
therapy 134 141 1525 1532 B-treatment
( 142 143 1533 1534 O
as 143 145 1534 1536 O
appropriate 146 157 1537 1548 O
to 158 160 1549 1551 O
subjects 161 169 1552 1560 O
with 170 174 1561 1565 O
existing 175 183 1566 1574 O
bone 184 188 1575 1579 O
marrow 189 195 1580 1586 O
disease 196 203 1587 1594 O
or 204 206 1595 1597 O
for 207 210 1598 1601 O
whom 211 215 1602 1606 O
bone 216 220 1607 1611 O
marrow 221 227 1612 1618 O
examination 228 239 1619 1630 O
is 240 242 1631 1633 O
a 243 244 1634 1635 O
component 245 254 1636 1645 O
of 255 257 1646 1648 O
disease 258 265 1649 1656 O
status 266 272 1657 1663 O
assessment 273 283 1664 1674 O
) 283 284 1674 1675 O

